Skip to main content

Table 1 Clinical characteristics at the eight-year study visit comparing children with juvenile idiopathic arthritis with and without information on physical education (PE) and school attendance

From: Participation in school and physical education in juvenile idiopathic arthritis in a Nordic long-term cohort study

Characteristics at final study visit (n = 347)

Participants with information on PE or school attendance (n = 285)

Participants without information on PE or school attendance (n = 62)

N

n (%) or median (IQR)

N

n (%) or median (IQR)

Female, n (%)

285

188 (66.0)

62

39 (62.9)

Age at disease onset, years

285

5.3 (2.3–9.4)

62

8.3 (3.8–11.2)

Cumulative joint count

285

6 (2–12)

62

4 (2–10)

Active joints

285

0.0 (0.0–0.0)

62

0.0 (0.0–0.0)

Physician GA, VAS

192

0.0 (0.0–0.9)

4

0.3 (0.1–1.8)

Patient/parent GA, VAS

216

0.0 (0.0–1.2)

3

0.3 (0.0–0.5)

Pain VAS

220

0.0 (0.0–1.3)

3

0.0 (0.0–0.5)

CHAQ score

285

0.0 (0.0–0.1)

8

0.0 (0.0–0.1)

CHQ-PF50, PhS score

160

52.5 (45.5–56.9)

4

46.8 (36.2–53.9)

CHQ-PF50, PsS score

160

54.8 (48.0–59.6)

4

40.9 (32.4–46.8)

DMARDs, n (%)

285

102 (35.8)

62

8 (12.9)

Oligoarticular persistent, n (%)

285

84 (29.5)

62

25 (40.3)

Oligoarticular extended, n (%)

285

49 (17.2)

62

8 (12.9)

Polyarticular RF negative, n (%)

285

58 (20.3)

62

7 (11.3)

Polyarticular RF positive, n (%)

285

2 (0.7)

62

1 (1.6)

Systemic arthritis, n (%)

285

8 (2.8)

62

1 (1.6)

Psoriatic arthritis, n (%)

285

13 (4.6)

62

0 (0)

Enthesitis-related arthritis, n (%)

285

29 (10.2)

62

12 (19.3)

Undifferentiated arthritis, n (%)

285

42 (14.7)

62

8 (12.9)

ESR mm/hour

193

7.0 (4.0–11.0)

14

8.5 (6.0–14.0)

CRP mg/liter

201

0.0 (0.0–5.0)

12

2.5 (0.0–7.5)

RF positive, n (%)

150

5 (3.3)

29

2 (6.9)

HLA-B27 positive, n (%)

274

62 (22.6)

52

11 (21.2)

ANA positive, n (%)

284

66 (23.2)

60

13 (21.7)

  1. Values are the median (interquartile range, IQR), unless indicated otherwise. PE Physical education and school attendance assessed at the eight-year study visit, GA Global assessment, VAS Visual analogue scale, CHAQ Childhood health assessment questionnaire, CHQ-PF50 Child health questionnaire parent form, PhS Physical summary score, PsS Psychological summary score, DMARDs Disease-modifying antirheumatic drugs including biologics used at the final study visit, ESR Erythrocyte sedimentation rate, CRP C-reactive protein, ANA Antinuclear antibody, assessed twice with at least 3 months interval, RF Rheumatoid factor, assessed twice with at least 3 months interval, HLA-B27 Human leucocyte antigen